December 9, 2024 11:15 AM EST
R&D
Pharma

Ab­b­Vie de­clares third Phase 3 Parkin­son’s win from Cerev­el takeover

Ayisha Sharma

News Reporter

There’s a sil­ver lin­ing for Ab­b­Vie on its close­ly-fol­lowed buy­out of Cerev­el: The phar­ma com­pa­ny re­port­ed Mon­day that its Parkin­son’s dis­ease can­di­date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Re­silience cuts 120 em­ploy­ees at a for­mer blue­bird gene ther­a­py site

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

A service from the Financial Times